Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 May 18;65(6):e02718-20.
doi: 10.1128/AAC.02718-20. Print 2021 May 18.

Whole-Genome Analysis Surveillance of Influenza A Virus Resistance to Polymerase Complex Inhibitors in Eastern Spain from 2016 to 2019

Beatriz Mengual-Chuliá  1 , Andrés Alonso-Cordero  1 , Laura Cano  1 , M Del Mar Mosquera  2 , Patricia de Molina  2 , Roser Vendrell  2 , Mariana Reyes-Prieto  3 , Mireia Jané  4 , Nuria Torner  4 , Ana Isabel Martínez  4 , Jordi Vila  2 , Javier Díez-Domingo  5 , M Ángeles Marcos #  2 , F Xavier López-Labrador #  6   7
Affiliations

Whole-Genome Analysis Surveillance of Influenza A Virus Resistance to Polymerase Complex Inhibitors in Eastern Spain from 2016 to 2019

Beatriz Mengual-Chuliá et al. Antimicrob Agents Chemother. .

Abstract

Molecular surveillance by whole-genome sequencing was used to monitor the susceptibility of circulating influenza A viruses to three polymerase complex inhibitors. A total of 12 resistance substitutions were found among 285 genomes analyzed, but none were associated with high levels of resistance. Natural resistance to these influenza A antivirals is currently uncommon.

Keywords: antivirals; baloxavir; favipiravir; next-generation sequencing; pimodivir; whole-genome sequencing.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. Furuta Y, Takahashi K, Kuno-Maekawa M, Sangawa H, Uehara S, Kozaki K, Nomura N, Egawa H, Shiraki K. 2005. Mechanism of action of T-705 against influenza virus. Antimicrob Agents Chemother 49:981–986. doi:10.1128/AAC.49.3.981-986.2005. - DOI - PMC - PubMed
    1. Furuta Y, Komeno T, Nakamura T. 2017. Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase. Proc Jpn Acad Ser B Phys Biol Sci 93:449–463. doi:10.2183/pjab.93.027. - DOI - PMC - PubMed
    1. Clark MP, Ledeboer MW, Davies I, Byrn RA, Jones SM, Perola E, Tsai A, Jacobs M, Nti-Addae K, Bandarage UK, Boyd MJ, Bethiel RS, Court JJ, Deng H, Duffy JP, Dorsch WA, Farmer LJ, Gao H, Gu W, Jackson K, Jacobs DH, Kennedy JM, Ledford B, Liang J, Maltais F, Murcko M, Wang T, Wannamaker MW, Bennett HB, Leeman JR, McNeil C, Taylor WP, Memmott C, Jiang M, Rijnbrand R, Bral C, Germann U, Nezami A, Zhang Y, Salituro FG, Bennani YL, Charifson PS. 2014. Discovery of a novel, first-in-class, orally bioavailable azaindole inhibitor (VX-787) of influenza PB2. J Med Chem 57:6668–6678. doi:10.1021/jm5007275. - DOI - PubMed
    1. Gubareva LV, Mishin VP, Patel MC, Chesnokov A, Nguyen HT, De La Cruz J, Spencer S, Campbell AP, Sinner M, Reid H, Garten R, Katz JM, Fry AM, Barnes J, Wentworth DE. 2019. Assessing baloxavir susceptibility of influenza viruses circulating in the United States during the 2016/17 and 2017/18 seasons. Euro Surveill 24:180066. doi:10.2807/1560-7917.ES.2019.24.3.1800666. - DOI - PMC - PubMed
    1. Goldhill DH, Te Velthuis AJW, Fletcher RA, Langat P, Zambon M, Lackenby A, Barclay WS. 2018. The mechanism of resistance to favipiravir in influenza. Proc Natl Acad Sci U S A 115:11613–11618. doi:10.1073/pnas.1811345115. - DOI - PMC - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources